Preclinical services for HIV therapeutics
Active Awarded Last action
- Contract number
- 75N93021D00004
- Awardee
-
Research Triangle Institute UEI JJHCMK4NT5N3
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Task orders
- 5 $2,060,112 obligated
Award facts
- Opportunity
-
- Preclinical Services for HIV Therapeutics Pre-Solicitation · 75N93019R00021 · Posted Oct 4, 2019
- Preclinical Services for HIV Therapeutics Solicitation · Posted Dec 5, 2019
- Combined order value
- $2,060,112 Current and potential, with all options
- Last date to order 87% complete
- IDV ceiling 2% used
- $107,274,471.00
- Award type
- Multiple award
- Who can order
- Only the awarding agency
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 3 offers Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this IDV
This indefinite delivery contract was awarded by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to provide preclinical development support for candidate products addressing HIV, HBV, HCV and other infectious diseases. The multiple award ID/IQ contract holds a potential value of $107 million and a period of performance from October 2020 through October 2027.
The contract establishes seven task areas for procuring services such as in vitro testing, synthesis of therapeutic agents, small animal models, formulation development, preclinical pharmacology/toxicology, and a reagent program. Task orders to date have funded screening of antiviral agents, confirmatory assays, development of a quality plan, and the minimum contract amount. Task Area B for synthesis is set aside for small businesses.
Work will be performed at the prime contractor's North Carolina location and aims to support product development from discovery through clinical trials. By providing preclinical resources, the contract seeks to advance promising candidates and fill development gaps to accelerate clinical testing, with an emphasis on HIV but also addressing HBV, HCV and other public health threats.
Task orders
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $0 |
Subawards
| Subcontractor | Amount | Awarded |
|---|---|---|
| Imquest Biosciences, Inc. | $31,626 | |
| Imquest Biosciences, Inc. | $49,390 | |
| Imquest Biosciences, Inc. | $133,835 | |
| Chemdiv, Inc. | $34,980 | |
| Imquest Biosciences, Inc. | $25,048 | |
| Imquest Biosciences, Inc. | $265,963 |
Quick answers
Who was awarded contract 75N93021D00004?
75N93021D00004 was awarded to Research Triangle Institute by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on October 15, 2020.
How much is contract 75N93021D00004 worth?
Orders under 75N93021D00004 have obligated $2,060,112. 75N93021D00004's own ceiling is $107,274,471.
How many orders have been placed under contract 75N93021D00004?
5 orders have been placed under 75N93021D00004, the latest on August 1, 2024.
Who can order from contract 75N93021D00004?
75N93021D00004 is a multiple award indefinite delivery contract. Only the awarding agency can place orders on it.
Is contract 75N93021D00004 part of a contract vehicle?
Yes. 75N93021D00004 is part of Preclinical Services for HIV Therapeutics.
Was contract 75N93021D00004 competed?
The extent of competition for 75N93021D00004 was full and open competition. The government received 3 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV